438 related articles for article (PubMed ID: 9851551)
1. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes.
Yamamoto A; Hoshi K; Ichihara K
Eur J Pharmacol; 1998 Nov; 361(1):143-9. PubMed ID: 9851551
[TBL] [Abstract][Full Text] [Related]
2. Antioxidative effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on peroxidation of phospholipid liposomes.
Yamamoto A; Ichihara K; Hoshi K
J Pharm Pharmacol; 2001 Feb; 53(2):227-32. PubMed ID: 11273020
[TBL] [Abstract][Full Text] [Related]
3. [Antioxidative effects of fluvastatin, and its major metabolites].
Nakashima A; Ohtawa M; Masuda N; Morikawa H; Bando T
Yakugaku Zasshi; 1999 Jan; 119(1):93-9. PubMed ID: 9922713
[TBL] [Abstract][Full Text] [Related]
4. [Antioxidative effects of fluvastatin, and its major metabolites [II]].
Nakashima A; Ohtawa M; Masuda N; Morikawa H; Iwasaki K
Yakugaku Zasshi; 2001 Jan; 121(1):113-6. PubMed ID: 11201159
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of fluvastain and its metabolites on the formation of several reactive oxygen species.
Nakashima A; Ohtawa M; Iwasaki K; Wada M; Kuroda N; Nakashima K
Life Sci; 2001 Aug; 69(12):1381-9. PubMed ID: 11531162
[TBL] [Abstract][Full Text] [Related]
6. Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity.
Bandoh T; Sato EF; Mitani H; Nakashima A; Hoshi K; Inoue M
Biol Pharm Bull; 2003 Jun; 26(6):818-22. PubMed ID: 12808293
[TBL] [Abstract][Full Text] [Related]
7. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor.
Suzumura K; Yasuhara M; Tanaka K; Odawara A; Narita H; Suzuki T
Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):1010-2. PubMed ID: 10434403
[TBL] [Abstract][Full Text] [Related]
8. EPR studies on hydroxyl radical-scavenging activities of pravastatin and fluvastatin.
Vandjelovic N; Zhu H; Misra HP; Zimmerman RP; Jia Z; Li Y
Mol Cell Biochem; 2012 May; 364(1-2):71-7. PubMed ID: 22207075
[TBL] [Abstract][Full Text] [Related]
9. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver.
Kocarek TA; Reddy AB
Drug Metab Dispos; 1996 Nov; 24(11):1197-204. PubMed ID: 8937853
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Yamamoto A; Itoh S; Hoshi K; Ichihara K
Experientia; 1995 Mar; 51(3):223-6. PubMed ID: 7698284
[TBL] [Abstract][Full Text] [Related]
11. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action.
Sumi D; Hayashi T; Thakur NK; Jayachandran M; Asai Y; Kano H; Matsui H; Iguchi A
Atherosclerosis; 2001 Apr; 155(2):347-57. PubMed ID: 11254905
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug.
Hagiwara M; Kataoka K; Arimochi H; Kuwahara T; Nakayama H; Ohnishi Y
World J Gastroenterol; 2005 Feb; 11(7):1040-3. PubMed ID: 15742411
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma.
Aoki S; Ikeda K; Yamamura M; Kojo S
Biol Pharm Bull; 2001 Feb; 24(2):123-6. PubMed ID: 11217077
[TBL] [Abstract][Full Text] [Related]
14. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
Transon C; Leemann T; Dayer P
Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of fluvastatin, an HMG-CoA reductase inhibitor, on the formation of 8-oxo-2'-deoxyguanosine in the nuclear DNA of hamster pancreas after a single administration of N-nitrosobis(2-oxopropyl)amine.
Kaneko T; Tahara S; Takabayashi F
Biol Pharm Bull; 2003 Sep; 26(9):1245-8. PubMed ID: 12951466
[TBL] [Abstract][Full Text] [Related]
16. Free radical scavenging and inhibition of lipid peroxidation by magnesium lithospermate B.
Wu XJ; Wang YP; Wang W; Sun WK; Xu YM; Xuan LJ
Acta Pharmacol Sin; 2000 Sep; 21(9):855-8. PubMed ID: 11501171
[TBL] [Abstract][Full Text] [Related]
17. HTHQ (1-O-hexyl-2,3,5-trimethylhydroquinone), an anti-lipid-peroxidative compound: its chemical and biochemical characterizations.
Hino T; Kawanishi S; Yasui H; Oka S; Sakurai H
Biochim Biophys Acta; 1998 Sep; 1425(1):47-60. PubMed ID: 9813237
[TBL] [Abstract][Full Text] [Related]
18. Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition.
Bandoh T; Mitani H; Niihashi M; Kusumi Y; Kimura M; Ishikawa J; Totsuka T; Sakurai I; Hayashi S
J Cardiovasc Pharmacol; 2000 Jan; 35(1):136-44. PubMed ID: 10630744
[TBL] [Abstract][Full Text] [Related]
19. Fluvastatin normalizes the decreased turnovers of glutathione and ascorbic acid in Watanabe heritable hyperlipidaemic rabbits.
Suzumura K; Kasahara E; Ohnishi Y; Chien KC; Inoue M
Clin Exp Pharmacol Physiol; 2000 Sep; 27(9):709-14. PubMed ID: 10972538
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of fluvastatin against reactive oxygen species induced DNA damage and mutagenesis.
Imaeda A; Aoki T; Kondo Y; Hori M; Ogata M; Obayashi H; Hasegawa G; Nakamura N; Tokuda K; Nishino H; Yoshikawa T; Kondo M
Free Radic Res; 2001 Jan; 34(1):33-44. PubMed ID: 11234994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
